Home › Modalities › Gene Therapy

Gene Therapy (24 companies)

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
FDMT 4D Molecular Therapeutics OphthalmologyRespiratory Rare 5 Phase 3 $608M 5
BEAM Beam Therapeutics HematologyMetabolic+1 Rare 1 Phase 2 $2.14B 6
CADL Candel Therapeutics Oncology 4 Phase 3 $424M 4
CGON CG Oncology Oncology 1 NDA Submitted $7.05B 1
GNLX Genelux Oncology 3 Phase 3 $96.1M 3
IBRX ImmunityBio Infectious DiseaseOncology 3 Approved $6.66B 17
INSM Insmed CardiovascularImmunology+3 Rare 2 Approved $26.7B 15
NTLA Intellia Therapeutics CardiovascularImmunology Rare 3 NDA Submitted $1.37B 3
LXEO Lexeo Therapeutics CardiovascularNeurology Rare 8 Phase 2 $236M 12
MGTX MeiraGTx ImmunologyMetabolic+2 Rare 16 Phase 3 $827M 16
NGNE Neurogene Neurology Rare 1 Phase 3 $478M 1
OCGN Ocugen Infectious DiseaseOphthalmology Rare 8 Phase 3 $257M 12
ONCY Oncolytics Biotech Oncology 3 Phase 2 $51.7M 4
IRD Opus Genetics Ophthalmology Rare 8 Approved $391M 12
DTIL Precision Biosciences Infectious DiseaseMetabolic+1 Rare 4 Phase 1 $197M 5
REPL Replimune Group Oncology 5 Approved $1.87B 5
RCKT Rocket Pharmaceuticals CardiovascularImmunology Rare 4 Approved $236M 4
SANA Sana Biotechnology MetabolicOncology 2 Phase 1 $563M 4
SRPT Sarepta Therapeutics NeurologyRespiratory Rare 2 Approved $1.58B 11
SLDB Solid Biosciences CardiovascularNeurology Rare 6 Phase 3 $695M 6
TSHA Taysha Gene Therapies Neurology Rare 4 Phase 3 $1.30B 4
RARE Ultragenyx Pharmaceutical CardiovascularMetabolic+1 Rare 3 Approved $1.70B 10
QURE uniQure HematologyMetabolic+1 Rare 4 Approved $1.46B 4
VYGR Voyager Therapeutics MetabolicNeurology Rare 4 Phase 1 $94.6M 9